Active Ingredient: Orlistat
Orlistat associated subacute hepatic failure. J Hepatol; 34: 173. Taehan Kan Hakhoe Chi. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
Diabetes Care. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Rom J Gastroenterol. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Diabetes Obes Metab.
XENical in the prevention of diabetes in obese subjects XENDOS study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. Orlistat Xenical -induced subacute liver failure.
Eur J Gastroenterol Hepatol. Severe hepatic injury caused by orlistat. Am J Med; 119; 37. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
Yet as suggested people can plan better- like take one hour before main meal of the day being 60 mg.
They are sold in 60 mg tablets as well- typically half the price. Xenical does not increase fat burning via increased Metabolic rate- digests less fat and more fat passes through. Will not help much if you UP your sugars, etc.
Most overweight people do not succeed on this product but as one person here lost 12 kg- they had a great method...